Dynamin-1 is a potential mediator in Cancer-Related Cognitive Impairment
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Dynamin-1 (DNM1) is reduced in cancer patients, especially those experiencing cognitive impairment during treatment. This downregulation of Dynamin-1 is linked to cancer-related cognitive impairment (CRCI) in both human and animal models.
Area Of Science
- Neuroscience
- Oncology
- Pharmacology
Background
- Dynamin-1 (DNM1) plays a crucial role in synaptic function and memory consolidation.
- DNM1 has been investigated as a potential therapeutic target for Alzheimer's disease.
- Cancer-related cognitive impairment (CRCI) is a significant concern for cancer patients, affecting quality of life.
Purpose Of The Study
- To investigate the role of Dynamin-1 (DNM1) in the pathogenesis of cancer-related cognitive impairment (CRCI).
- To examine DNM1 levels in adolescent and young adult (AYA) cancer patients and a preclinical mouse model.
- To determine if DNM1 downregulation is associated with cognitive deficits in cancer patients undergoing treatment.
Main Methods
- A two-prong approach using human and animal models.
- Human study: 86 participants (30 AYA cancer, 56 controls) completed cognitive assessments (FACT-Cog) and blood draws at multiple time points.
- Animal study: A syngeneic mouse model of breast cancer was used to assess DNM1 expression in the brain, particularly in hippocampal subregions, following chemotherapy.
Main Results
- DNM1 levels were significantly lower in cancer participants compared to non-cancer controls prior to treatment.
- Cognitively impaired cancer patients showed significant DNM1 downregulation during treatment, unlike unimpaired patients.
- Chemotherapy in the mouse model led to a significant decrease in DNM1 immunoreactivity in the hippocampal CA1 and CA3 subregions.
Conclusions
- Downregulation of Dynamin-1 (DNM1) is consistently observed in both human and animal studies and is linked to the onset of cancer-related cognitive impairment (CRCI).
- These findings suggest a potential role for DNM1 in CRCI pathogenesis.
- Further research is warranted to explore DNM1 as a therapeutic target for CRCI.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Guanine nucleotide exchange factors or GEF,
GTPase-activating proteins or GAPs, and
Guanine nucleotide-dissociation inhibitors or GDIs.
The GEF activates the GTPase by exchanging the bound-GDP with GTP. The...
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...